Moreover, in human T-ALL cells devoid of PTEN, pharmacological blockade of both p110γ and p110δ impacted on tumor cell proliferation and survival, supporting the relevance of these isoforms as therapeutic targets for T-ALL treatment [14]. The gene discussed is PTEN; the disease is acute lymphoblastic leukemia.